|
|
| Undisclosed PARP7 inhibitor / Duke Street Bio (0 Trials) |
|
| Undisclosed PARP7 inhibitor / Denovicon (0 Trials) |
|
| Undisclosed Partnered TriNKETs / Dragonfly Therap, BMS (0 Trials) |
|
| Undisclosed PD-1 inhibitor / BMS, Halozyme (0 Trials) |
|
| Undisclosed PD-1 monoclonal antibody / Jiangsu Pacific Meinuoke Biopharmaceutical (0 Trials) |
|
| Undisclosed PD-1 x CTLA-4 trispecific TRIDENT / MacroGenics (0 Trials) |
|
| Undisclosed PD-L1 inhibitor / NeoTX (0 Trials) |
|
| Undisclosed PD-L1 mAb / JSR Life Sciences (0 Trials) |
|
| Undisclosed PD-L1/BCMA bispecific antibody therapeutic / Immune Pharma (0 Trials) |
|
| Undisclosed PD-L1/CTLA-4 bispecific antibody therapeutic / Sorrento (0 Trials) |
|
| Undisclosed PD1 antagonist mAb / North Coast Biologics (0 Trials) |
|
| Undisclosed PD1 x IL15/IL15Rα bispecific antibody therapeutic / Xencor (0 Trials) |
|
| Undisclosed PD1 x TGFβR2 XmAb therapeutic / Xencor (0 Trials) |
|
| Undisclosed PD1-TIM3 bispecific antibody / BMS (0 Trials) |
|
| Undisclosed PD1/LILRB1 BiTE / Amgen (0 Trials) |
|
| Undisclosed PDE4B inhibitor / Shionogi (0 Trials) |
|
| Undisclosed PDL1 x CD28 XmAb bsAb therapeutic / Xencor (0 Trials) |
|
| Undisclosed personalized mRNA-based vaccine / Greenlight Biosci, EpiVax (0 Trials) |
|
| Undisclosed PI3K/PARP dual inhibitor / SignalRx (0 Trials) |
|
| Undisclosed PKC theta inhibitor / EpiAxis Therap (0 Trials) |
|
| Undisclosed PKCθ modulator / Evommune (0 Trials) |
|
| Undisclosed PKMYT1 inhibitor / Acrivon Therap (0 Trials) |
|
| Undisclosed PLK1 inhibitor / Fosun Pharma (0 Trials) |
|
| Undisclosed PLK1 PROTAC / Icure Pharm (0 Trials) |
|
| Undisclosed PLK4 inhibitor / Qilu Pharma (0 Trials) |
|
| Undisclosed post-infection cough therapeutic / Nocion Therap (0 Trials) |
|
| Undisclosed Prep-inhibitor / Bayer, Healthgen Biotech (0 Trials) |
|
| Undisclosed PRMT5 inhib / Lead Pharma (0 Trials) |
|
| Undisclosed PRMT5 inhib / Ohio State University (0 Trials) |
|
| Undisclosed prostate cancer therapeutic / Esfam Biotech (0 Trials) |
|
| Undisclosed prostate cancer therapeutic / Philogen (0 Trials) |
|
| Undisclosed PROTAC degrader / Arvinas, Bayer (0 Trials) |
|
| Undisclosed PROTAC degrader / Pin Therap (0 Trials) |
|
| Undisclosed protease inhibitor / Virna Therap (0 Trials) |
|
| Undisclosed Protein A degrader / Degron Therap (0 Trials) |
|
| undisclosed protein degradation therapeutic / Amgen, Plexium (0 Trials) |
|
| Undisclosed protein degradation therapeutic / Frontier Medicines, AbbVie (0 Trials) |
|
| Undisclosed PSMA TriKE / GT Biopharma (0 Trials) |
|
| Undisclosed RA targeted cell therapy / MaxCyte (0 Trials) |
|
| Undisclosed RAD52 inhibitor / Satya Pharma (0 Trials) |
|
| Undisclosed radiopharmaceutical / BMS (0 Trials) |
|
| Undisclosed radiopharmaceutical / ZielBio (0 Trials) |
|
| Undisclosed RAF1 inhibitor / Quanta Therap (0 Trials) |
|
| Undisclosed RAS pathway targeting therapeutic / Ikena Oncology (0 Trials) |
|
| Undisclosed renal disease therapeutic / Goldfinch Bio (0 Trials) |
|
| Undisclosed renal medullary carcinoma therapeutic vaccine / Calviri (0 Trials) |
|
| Undisclosed rheumatoid arthritis gene therapy / MeiraGTx (0 Trials) |
|
| Undisclosed rheumatoid arthritis therapeutic / Istesso (0 Trials) |
|
| Undisclosed RIPK1 inhibitor / Rigel (0 Trials) |
|
| Undisclosed RNA targeting CNS therapeutic / Lundbeck, Rgenta Therap (0 Trials) |
|
| Undisclosed RNAi therapeutic / Alnylam (0 Trials) |
|
| Undisclosed ROR1 TriKE / GT Biopharma (0 Trials) |
|
| Undisclosed ROR1 x CD137 based bispecific antibody / Crescendo Biologics (0 Trials) |
|
| Undisclosed RUNX1 mRNA therapeutic / NANO MRNA (0 Trials) |
|
| Undisclosed SCA therapeutic / Locana (0 Trials) |
|
| Undisclosed SCA-3 therapeutic / PTC Therap (0 Trials) |
|
| Undisclosed SCF/KIT bispecific therapeutic / Celldex (0 Trials) |
|
| Undisclosed SCLC therapeutic / Auransa (0 Trials) |
|
| undisclosed SCLC therapeutic / Omega Therap (0 Trials) |
|
| Undisclosed scleroderma therapeutic / Radboud University, LightOx (0 Trials) |
|
| Undisclosed second-generation vaccibody vaccine / Nykode Therap (0 Trials) |
|
| Undisclosed selective FGFR2 inhibitor / Applied Pharmaceutical Sci (0 Trials) |
|
| Undisclosed selective SMARCA2 degrader therapeutics / Foghorn Therap, Eli Lilly (0 Trials) |
|
| Undisclosed Short Bowel Syndrome therapeutic / Surrozen (0 Trials) |
|
| Undisclosed siRNA based therapeutic / PharmaMar (0 Trials) |
|
| Undisclosed siRNA/Gal-1 therapeutic / Ovensa (0 Trials) |
|
| Undisclosed SIRP alpha mab / Arch Oncology (0 Trials) |
|
| Undisclosed SIRPA inhibitor mAb / Biocytogen (0 Trials) |
|
| Undisclosed SIRPαxPD-L1 bispecific therapeutic / Compass Therap (0 Trials) |
|
| Undisclosed skeletal muscle activators / Cytokinetics (0 Trials) |
|
| Undisclosed SLC15A4 inhibitor / OMass Therap (0 Trials) |
|
| Undisclosed SMAC mimetic / HQL Pharma (0 Trials) |
|
| Undisclosed small molecule degrader / Captor Therap, Ono Pharma (0 Trials) |
|
| Undisclosed SMARCA2 inhibitor / Cancer Research UK (0 Trials) |
|
| Undisclosed SMARCA2/4 degrader / Roivant (0 Trials) |
|
| Undisclosed SmartDepot SR therapeutic / Peptron (0 Trials) |
|
| Undisclosed SNA based therapeutics for Huntington's disease / Exicure (0 Trials) |
|
| Undisclosed SNAP-CAR T therapy / Coeptis (0 Trials) |
|
| Undisclosed soluble interleukin-17 receptor C therapeutics / EMD Serono (0 Trials) |
|
| Undisclosed SOS1 inhibitor / Vrise Therap (0 Trials) |
|
| Undisclosed STAT3 iTAb / Sorrento (0 Trials) |
|
| Undisclosed STING agonist / Ryvu Therap, BioNTech (0 Trials) |
|
| Undisclosed STING antagonist / Nimbus Therap, BMS (0 Trials) |
|
| Undisclosed STING inhibitors / StingInn (0 Trials) |
|
| Undisclosed survivin mRNA cancer immunotherapeutic vaccine / Regen BioPharma (0 Trials) |
|
| Undisclosed synthetic lethal therapeutic / AtlasMedx (0 Trials) |
|
| Undisclosed synthetic lethal therapeutic / Ryvu Therap (0 Trials) |
|
| Undisclosed synthetic lethal therapeutic / Foghorn Therap (0 Trials) |
|
| Undisclosed TAAxCD28 XmAb bispecific therapeutic / Xencor, J&J (0 Trials) |
|
| Undisclosed TARP peptide vaccine / National Cancer Institute, PDS Biotech (0 Trials) |
|
| Undisclosed tau antibody therapeutic / Axon Neurosci (0 Trials) |
|
| Undisclosed tau antibody therapeutic / ProMIS Neurosci (0 Trials) |
|
| Undisclosed tau degrader / APRINOIA Therap (0 Trials) |
|
| Undisclosed tau inhibitor / Wren Therap (0 Trials) |
|
| Undisclosed tau oligomerization inhibitor / Axon Neurosci (0 Trials) |
|
| Undisclosed TDP oligomer inhibitor / Treventis Corp (0 Trials) |
|
| Undisclosed TDP-43 inhibitor / Wren Therap (0 Trials) |
|
| Undisclosed TDP-43 inhibitor / BMS, Prothena (0 Trials) |
|
| Undisclosed TGF-β inhibitor / Inventiva (0 Trials) |
|
| Undisclosed therapeutic / University of Edinburgh (0 Trials) |
|
| Undisclosed therapeutic 1 for COVID19 / Afecta Pharma (0 Trials) |
|
| Undisclosed therapeutic 2 for COVID19 / Afecta Pharma (0 Trials) |
|
| Undisclosed therapeutic for Alzheimer's Disease / J&J (0 Trials) |
|
| Undisclosed therapeutic for Parkinson's Disease / J&J (0 Trials) |
|
| Undisclosed therapeutic for Parkinson's disease / NeuExCell Therap (0 Trials) |
|
| Undisclosed therapeutic for Parkinson's Disease / 3z Pharma (0 Trials) |
|
| Undisclosed therapy for diabetic retinopathy / Calpain Therap (0 Trials) |
|
| undisclosed therapy for ischaemic retinal vein occlusion / Calpain Therap (0 Trials) |
|
| Undisclosed TIGIT ETB / Molecular Templates (0 Trials) |
|
| Undisclosed TIM-3 antagonist mAb / Arcus Biosci (0 Trials) |
|
| Undisclosed TIM-3 inhibitor / Interprotein Corp (0 Trials) |
|
| Undisclosed TIM3 inhibitor / Grifols (0 Trials) |
|
| Undisclosed TLR8 agonist ADC / ARS Pharma (0 Trials) |
|
| Undisclosed TMD1 targeting CF therapeutic / Sionna Therap (0 Trials) |
|
| Undisclosed tpl2 kinase inhibitors / Pfizer (0 Trials) |
|
| Undisclosed TRACER AAV Capsid based gene therapy / Pfizer, Voyager (0 Trials) |
|
| Undisclosed transcription factor modulator / Roche, Kronos Bio (0 Trials) |
|
| Undisclosed translation medicine for rare disease / Insmed (0 Trials) |
|
| Undisclosed TREM-2 inhibitor / SignaBlok (0 Trials) |
|
| Undisclosed TriNKETs / Dragonfly Therap (0 Trials) |
|
| Undisclosed TrispecificAB / Affimed (0 Trials) |
|
| Undisclosed TROP-2 ADC / Fontacea (0 Trials) |
|
| Undisclosed Trop2-targeted ETB / Molecular Templates (0 Trials) |
|
| Undisclosed TROP2-TRACTr / Janux Therapeutics (0 Trials) |
|
| Undisclosed TROP2xCD28 bispecific TCE POWERbody / Adagene (0 Trials) |
|
| Undisclosed TRPC6 antagonist / Algomedix (0 Trials) |
|
| Undisclosed TRPM7 agonist / Zhongze Therap (0 Trials) |
|
| Undisclosed uveal melanoma therapeutic / Regeneron (0 Trials) |
|
| Undisclosed VLP vaccine / Allergy Therap (0 Trials) |
|
| Undisclosed WEE1 degrader / Degron Therap (0 Trials) |
|
| Undisclosed WEE1 inhibitor / Wigen Biomedicine (0 Trials) |
|
| Undisclosed WEE1 inhibitor / Sentinel Oncology (0 Trials) |
|
| Undisclosed WEE1 inhibitor / Acrivon Therap (0 Trials) |
|
| Undisclosed WEE1 inhibitor / Roivant (0 Trials) |
|
| Undisclosed WRN degrader / Beactica (0 Trials) |
|
| Undisclosed WRN inhibitor / Ryvu Therap (0 Trials) |
|
| Undisclosed WRN inhibitor / Syros (0 Trials) |
|
| Undisclosed WRN inhibitor / XPose Therap (0 Trials) |
|
| Undisclosed ɑPD-1xIL-2/15Rβγ agonist / Medikine (0 Trials) |
|
| Undisclosed α-synuclein inhibitor / Wren Therap (0 Trials) |
|
| Undisclosed α4β7 integrin inhibitor / C4X Discovery (0 Trials) |
|
| Undisclosed α4β7 integrin inhibitor / Eli Lilly (0 Trials) |
|
| Undisclosed α7nAChR program / 180 Life Sci (0 Trials) |
|
| Undisclosed γδ TCR ImmTAC therapy / Immunocore, Century Therap (0 Trials) |
|
| Undiscosed therapy / Nuredis (0 Trials) |
|
| unesbulin (BMIi-1) / PTC Therap (1 Trials) |
|
| UniAb based CAR-T therapeutic / Gilead (0 Trials) |
|
| UniCAR-T-CEA / AvenCell Therap (0 Trials) |
|
| UniCAR-T-PD-L1 / AvenCell Therap (0 Trials) |
|
| UniDab based CAR-T therapeutic / Amgen, Roche (0 Trials) |
|
| UniDab based CAR-T therapeutic / ArsenalBio, Amgen (0 Trials) |
|
| Uniflu (caffeine, codeine, vitamin C, diphenhydramine, paracetamol, phenylephrine) / Alliance (1 Trials) |
|
| Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma (13 Trials) |
|
| Universal CAR-T19 cells / Xinqiao Hospital (0 Trials) |
|
| universal chimeric antigen receptor-modified AT19 cells / Wuhan Union Hospital, Chengdu USino Techno (0 Trials) |
|
| universal flu vaccine (M-001) / Scinai Immunotherap (0 Trials) |
|
| Universal Influenza DNA Vaccine / GeneOne (0 Trials) |
|
| universal influenza vaccine (BPL-1357) / National Institute of Allergy and Infectious Diseases (0 Trials) |
|
| Unloxcyt (cosibelimab-ipdl) / Sun Pharma (3 Trials) |
|
| unmodified allogeneic gamma delta T cell therapy (TCB007) / TC Biopharm (0 Trials) |
|
| UP1002 / UPPTHERA (0 Trials) |
|
| UPA C-IUS (ulipristal acetate) / Perrigo Company (0 Trials) |
|
| UPA C-Ring (ulipristal acetate) / Perrigo Company (0 Trials) |
|
| upifitamab rilsodotin (XMT-1536) / Servier (1 Trials) |
|
| Uplizna (inebilizumab-cdon) / Amgen (29 Trials) |
|
| Upneeq (oxymetazoline hydrochloride) / RVL Pharma (0 Trials) |
|
| UPR Modulators / Astellas (0 Trials) |
|
| uprevstobart (INCA00186) / Incyte (0 Trials) |
|
| uprifosbuvir (IDX21437) / Merck (MSD) (2 Trials) |
|
| uproleselan (APL-106) / GlycoMimetics (2 Trials) |
|
| uprosertib (LAE003) / Laekna Therap (2 Trials) |
|
| Uptravi (selexipag) / J&J (9 Trials) |
|
| Uptravi Injection (selexipag IV) / J&J (0 Trials) |
|
| UPV-101 / UbiVac (0 Trials) |
|
| UQ-CSL V451 / University of Queensland (0 Trials) |
|
| UR-13870 / Uriach Pharma (0 Trials) |
|
| urabrelimab (SRF231) / Coherus Oncology (0 Trials) |
|
| Uracyst (sodium chondroitin sulfate) / Stellar Pharma (0 Trials) |
|
| URB597 / Merck (MSD) (0 Trials) |
|
| URB597-based ARN molecule / Exxel Pharma (0 Trials) |
|
| urea / Generic mfg. (0 Trials) |
|
| Urece (dotinurad) / Fuji Yakuhin, Mochida, Fortress, Eisai (0 Trials) |
|
| Urelle / Viatris (0 Trials) |
|
| urelumab (BMS-663513) / BMS, Ono Pharma (3 Trials) |
|
| Uriadec (topiroxostat) / Fuji Yakuhin, Suzuken (0 Trials) |
|
| Uribeta (IFN-beta-1b biosimilar) / Probiomed (0 Trials) |
|
| uridine nucleotide analog (IDX20963) / Merck (MSD) (0 Trials) |
|
| uridine triacetate (PN 401) / Wellstat (0 Trials) |
|
| URMC-099 / University of Rochester Medical Center (0 Trials) |
|
| URO-902 / Sumitomo Pharma (0 Trials) |
|
| Urocidin (mycobacterium cell wall-DNA complex) / Liminal BioSci (0 Trials) |
|
| urocortin II (NBI-69734) / Renova Therap (0 Trials) |
|
| urocortin-2 peptide agonist long acting / Eli Lilly (0 Trials) |
|
| Urodilatin (ularitide) / Cardiorentis (2 Trials) |
|
| Urolieve (lidocaine alkalized intravesicular) / Regent Pacific Group (6 Trials) |
|
| Uromune (MV140) / Inmunotek (0 Trials) |
|
| ursodeoxycholic acid / Generic mfg. (101 Trials) |
|
| ursodeoxycholic acid (STN1013600) / Santen (0 Trials) |
|
| Ursomax (ursodeoxycholic acid 150 mg/ 300 mg) / Emcure (0 Trials) |
|
| Usher syndrome type 2A therapy / Wave Life Sciences (0 Trials) |
|
|